Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Live combined Bifidobacterium and Lactobacillus tablets for prevention of post-TIPS hepatic encephalopathy
ChiCTR2200062996Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of bifidobacterium + lactobacillus in Cirrhosis and hepatic encephalopathy (HE) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Hepatic encephalopathy and Gut microbiota. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
bifidobacterium + lactobacillus
03
Conditions
Cirrhosishepatic encephalopathy (HE)
Beyond the preview
Go deeper on ChiCTR2200062996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062996.